Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COM701 maintenance therapy in relapsed platinum-sensitive ovarian cancer
2025-521125-33-00Phase 2Authorised
- Sponsor
- Compugen Ltd.
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised trial of COM701 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Compugen Ltd. Primary endpoint: Progression-free survival. Planned start Sep 2025; status: authorised.
02
Drugs
COM701
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2025-521125-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521125-33-00.